IU Health Arnett now offering FDA-approved treatment for Alzheimer’s

Indiana University Health Arnett Infusion Therapy now offers a first-of-its-kind treatment for early Alzheimer’s.

The treatment, a monoclonal antibody administered via biweekly intravenous (IV) infusions, is the first fully FDA-approved treatment for Alzheimer’s disease in the United States.

It works by reducing the accumulation of amyloid plaques in the brain caused by the disease—treating the disease itself, rather than the symptoms, thereby slowing the decline in cognitive function. It is only effective in patients with early-stage Alzheimer’s.

“While there is no cure for Alzheimer’s, this treatment can help people maintain their independence and thinking skills longer and give people more time to participate in daily life, while also providing more quality time before symptoms get worse,” says neurologist Hongkui Jing, MD, PhD. “For patients with Alzheimer’s and their loved ones, this extra time is precious.”

Nearly seven million Americans—one in nine people over the age of 65—are living with Alzheimer’s disease, and by 2050, that number is expected to almost double.

IU Health is the only healthcare provider offering this treatment in Greater Lafayette.

“If you or someone you love is having trouble with things like keeping track of paying bills, remembering names or completing familiar daily tasks, speak with your doctor. The thought of having that conversation can be scary, but the sooner this disease is found, the more likely we can help treat it and slow its progression,” says Jing.

Related: The end of the beginning for Alzheimer's patients